Balerion Senior Associate Aidan Daoussis sits down with Ambrosia Space Founder & CEO Mario Maggio to discuss in-space biomanufacturing and microgravity life sciences.
In this conversation, Mario outlines Ambrosia Space’s focus on building scalable biomanufacturing infrastructure designed to operate in microgravity, including bioreactors, centrifuges, and downstream processing systems. The discussion explains why microgravity can fundamentally change biological processes and how on-orbit manufacturing enables new capabilities for biopharma research, drug development, and life-science experimentation.
Aidan and Mario also cover Ambrosia’s first flight mission (ABBY), which will deploy a 2.5-liter bioreactor and centrifuge in orbit, providing an order-of-magnitude increase in on-orbit bioprocessing capability. The conversation situates in-space biomanufacturing within current commercial demand as well as long-term applications for NASA, the Department of Defense, and sustained human presence beyond Earth.
00:00 – Welcome & introductionsAidan introduces Mario Maggio and frames the discussion around biomanufacturing as emerging orbital infrastructure.
01:30 – Mario Maggio’s backgroundMario explains his path into space biomanufacturing and the motivation behind founding Ambrosia Space.
03:30 – What biomanufacturing means in microgravityHow microgravity alters biological processes compared to Earth-based manufacturing.
06:00 – Why space enables different outcomesDiscussion of sedimentation, shear forces, diffusion, and why orbit changes cell behavior and production pathways.
09:00 – Ambrosia Space’s technical focusOverview of scalable bioreactors, centrifuges, and downstream processing designed specifically for microgravity.
12:30 – The ABBY mission overviewDetails on Ambrosia’s first flight, including the 2.5-liter bioreactor and centrifuge payload.
16:00 – Order-of-magnitude capability jumpWhy current on-orbit life-science experiments are limited and how ABBY expands process development capacity.
19:00 – Applications in biopharmaHow in-space manufacturing supports drug discovery, formulation, and biologics research.
22:30 – NASA and government use casesRelevance for space agencies, national labs, and defense-driven life-science research.
26:00 – Designing hardware for microgravity operationsEngineering constraints, reliability requirements, and system autonomy in orbit.
29:30 – Downstream processing challengesWhy separation, concentration, and purification matter as much as upstream bioreactors.
33:00 – Commercialization pathwayHow Ambrosia plans to move from experimental payloads to repeatable commercial services.
36:30 – Scaling biomanufacturing in orbitWhat scaling looks like for space-based life-science infrastructure over the next decade.
40:00 – Role of private space stationsHow new commercial stations enable continuous biomanufacturing operations.
43:00 – Long-term visionWhy biomanufacturing is foundational for sustained human activity in orbit and beyond.
46:00 – Mars and deep-space relevanceHow microgravity bioprocessing ties into long-duration missions and off-world settlement.
48:30 – Closing thoughtsMario summarizes Ambrosia’s near-term milestones and long-term objectives.
